A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC)
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 11 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Dec 2016.